June 27, 2017
PHILADELPHIA — The use of cannabis products in the pediatric population for a variety of conditions, including seizures and psychiatric illnesses, has not been sufficiently supported by research to justify its use in this population, according to a recent presentation at the annual meeting of the American Association of Nurse Practitioners.
“There’s a level of complexity with this topic. You have a Schedule I drug, and you have kids,” Teri Moser Woo, PhD, RN, ARPN, CNL, CPNP, FAANP, from Pacific Lutheran University, said in the presentation. “Trying to get something like this through the Institutional Review Board and the Drug Enforcement Agency is incredibly difficult. These studies need special safes to store medicine, inspection of the safe, assurance that no one could get into the drug … you can see the issue in trying to get something approved like this for human subjects.”